Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule drugs for rare genetic diseases. Fulcrum's entire focus is on pociredir, a once-daily oral pill for sickle cell disease (SCD), a serious inherited blood disorder affecting roughly 100,000 people in the U.S. SCD causes abnormal hemoglobin that deforms red blood cells, leading to severe pain crises, organ damage, and shortened life expectancy. Pociredir works by inhibiting EED, a component of the PRC2 protein complex that silences fetal hemoglobin (HbF) production. Reactivating HbF is clinically meaningful because HbF does not sickle, and higher HbF levels are associated with fewer pain crises. Fulcrum completed its Phase 1b PIONEER trial, with the 20 mg cohort showing mean HbF increasing from 7.1% to 19.3% at 12 weeks, with 58% of patients reaching HbF levels of 20% or higher and no treatment-related serious adverse events. Fulcrum plans to initiate a registration-enabling trial in the second half of 2026, following FDA feedback expected in Q2 2026. Pociredir holds FDA orphan drug and fast track designations. Fulcrum has no marketed products and generates no product revenue, funding operations through cash on hand. If approved, Fulcrum plans to commercialize pociredir in the U.S. directly, targeting the concentrated base of hematologists who manage SCD patients.